Suven Pharmaceuticals Q2 Results Live: Profit Rise by 3.33% YOY

Suven Pharmaceuticals Q2 Results Live : Suven Pharmaceuticals declared their Q2 results on 12 Nov, 2024, showcasing a robust performance with a topline increase of 11.54% year-over-year. The company's profit saw a modest rise of 3.33% compared to the previous year, marking a positive trend in their financial health.

In comparison to the previous quarter, Suven Pharmaceuticals reported an impressive revenue growth of 11.72% along with a significant profit increase of 35.28%. This indicates a strong momentum in their operations and market presence.

However, the Selling, General & Administrative expenses rose sharply by 13.7% quarter-over-quarter and a staggering 81.51% year-over-year, raising concerns about cost management within the company.

On the operational front, the operating income saw a notable upturn of 30.84% quarter-over-quarter and a modest increase of 1.14% year-over-year, reflecting operational efficiency despite rising expenses.

For Q2, the Earnings Per Share (EPS) stood at ₹3.21, which is an increase of 2.56% year-over-year, indicating a slight improvement in profitability per share for investors.

In terms of stock performance, Suven Pharmaceuticals has experienced a -9.72% return in the last week, however, it boasts an impressive 84.53% return over the last six months and a 66.65% year-to-date return, showcasing strong long-term growth potential.

As of now, Suven Pharmaceuticals holds a market capitalization of ₹30,663.62 Crores with a 52-week high of ₹1,353.95 and a low of ₹558.50, suggesting substantial volatility in its stock price over the past year.

As of 13 Nov, 2024, all analysts covering the company have given a 'Strong Buy' rating, reflecting positive sentiment towards Suven Pharmaceuticals' future performance.